喜讯
华人抗体协会会刊Antibody Therapeutics 被Web of Science核心数据库ESCI收录，欢迎投稿！
为了促进华人抗体协会会员间的交流与合作，华人抗体协会特邀华人抗体协会企业会员对该企业最新的技术平台进行分享，隆重推出 Industrial Frontier Webinar Series。特别感谢华人抗体协会企业会员近岸蛋白对本次讲座的支持！
多次跨膜蛋白（Multipass transmembrane protein）包括GPCRs（G蛋白偶联受体）、离子通道和转运蛋白等，它们在细胞膜中扮演着重要的角色，并且与许多疾病的发生发展密切相关。这些蛋白质的结构复杂，通常包含多个跨膜结构域（TMDs），这导致了在表达和纯化过程中可能遇到的不稳定性、聚集等挑战。在小分子上市药物中，超过50%的靶点为多次跨膜蛋白。然而，这些药物可能存在特异性不足或参与多种信号通路而产生的不良影响，导致药物安全性和副作用问题。单克隆抗体（mAb）靶向多次跨膜蛋白是实现靶向选择的一种有效方法，但过去这些靶点常被认为难以成药或不可成药。
NovoiSMART®技术平台是由近岸蛋白推出的，针对结构复杂的多次跨膜蛋白抗体开发难的现状，提供多次跨膜靶点抗体开发的整体解决方案。本次讲座有幸邀请到近岸蛋白张冠阳博士介绍NovoiSMART®技术如何助力靶向多次跨膜蛋白的抗体药开发。
讲座时间为：美国东部时间2024年12月14日（周六）晚上9点-10点，北京时间2024年12月15日（周日）上午10点-11点
讲座语言为：英文
本期主讲人：张冠阳(Gavin Guanyang Zhang)博士
张冠阳(Gavin Guanyang Zhang)博士，毕业于美国加州大学河滨分校昆虫学专业，曾在亚利桑那州立大学和佛罗里达大学进行系统发育学和癌症表观遗传学方面的博士后研究，在Science, PLOS Biology, Systematic Biology, Molecular Phylogenetics and Evolution 等国际著名期刊上发表 20 余篇文章。目前在近岸蛋白担任科学事务与运营高级总监一职，致力于推进和推广近岸蛋白创新的抗体发现和重组蛋白制备平台，其中包括专有的 NovoiSMART® 多策略抗体开发技术平台。
"Gavin" Guanyang Zhang holds a PhD in Entomology from the University of California, Riverside, with postdoctoral research experience in phylogenetics and cancer epigenetics at Arizona State University and the University of Florida. Dr. Zhang has also published 20 articles in internationally renowned journals such as Science, PLOS Biology, Systematic Biology, Molecular Phylogenetics and Evolution. Currently, he is the Senior Director of Business & Operations at Novoprotein Scientific, where he leads strategic initiatives for advancing and promoting Novoprotein's innovative antibody and recombinant protein platforms, including the proprietary NovoiSMART® antibody development system.
讲座题目：助力未来:多次跨膜蛋白靶点抗体开发的机遇与挑战
摘要：随着全球药企在新药研发中持续投入，为实现关键突破和打造差异化管线，靶点选择至关重要。多次跨膜蛋白是连接细胞膜内外的重要渠道，参与多种信号传导、调控细胞对外界刺激的响应、与多种人类疾病密切相关，是理想药物靶点。但因其表达量少、稳定性差、溶解度低及纯化难等被定义为难成药靶点，因此迫切需要创新技术突破 “抗体开发难题”。
本次讲座将重点介绍近岸蛋白专有的多策略抗体开发技术平台 NovoiSMART®。该平台以多项核心技术为基础，通过多种策略进行多次跨膜蛋白免疫，结合亲和力和功能筛选获得候选分子。该平台的免疫技术可解决跨膜蛋白难题，讲座还将介绍抗原设计及抗体优化如何助力靶向多次跨膜蛋白的抗体药开发。
Webinar Title: Fueling the future: Opportunities and challenges in multi-pass membrane target antibody development
Abstract: With the continuous investment of major global pharmaceutical companies in new drug research and development, in order to achieve a key breakthrough and create a differentiated pipeline, the key lies in the target selection. Multi-pass membrane proteins serve as crucial channels connecting the intracellular and extracellular environments of cells, transmitting various signals and regulating cellular responses to external stimuli. Moreover, many human diseases are closely associated with abnormalities in the function of multi-pass membrane proteins, making them ideal targets for drug intervention. However, multi-pass membrane proteins are defined as difficult-to-drug or undruggable targets due to challenges such as low expression levels, poor stability, low solubility, and high purification complexity. Therefore, there is an urgent need for innovative strategies to break through the "difficulties in antibody development" faced by multi-pass membrane protein targets.
This lecture will focus on introducing NovoiSMART®, a technology for immunization and antibody screening of multi-pass membrane proteins based on multiple core technology platforms. By employing various strategies for immunizing multi-pass membrane proteins and combining affinity and functional screening, this technology enables the identification of candidate molecules. Moreover, the immunization technology of this platform can overcome the challenges faced by multi-pass membrane proteins. Meanwhile, the lecture will also introduce how the antigen design and antibody optimization of the platform help in the development of antibody drugs targeting multi-pass membrane proteins.
请点击二维码注册讲座
本期赞助商介绍
Novoprotein Scientific Inc. (Novoprotein) is a high-tech enterprise with more than 10 years of extensive experience in the recombinant protein industry, focusing on protein technology, and advanced in R&D, production, sales, and application solutions to raw materials and techniques for biopharmaceuticals, in vitro diagnosis, mRNA vaccines, and basic life science research. Our principal products include target proteins and cytokines, recombinant antibodies, molecular enzymes and reagents, as well as providing related technical services. Novoprotein possesses R&D and manufacturing bases in Shanghai, Suzhou, and Heze.
We have developed more than ten thousand of recombinant proteins and have independently researched and developed 7 comprehensive technology platforms and 23 core technologies, including protein design and modification, protein production and quality control, and protein application and evaluation. Novoprotein provides biomedical Industry customers with one-stop services from product development to technological innovation on the basis of a comprehensive technology system and in-house innovative raw materials.
We are the market leader in China in terms of mRNA raw enzymes and reagents, with the advanced large-scale production capacity of mRNA raw enzymes and product quality reaching an international advanced level.
Novoprotein is "Dedicated to Life Science with Innovation and Focus". The protein tools and techniques promote the innovation upgrade of the biopharmaceutical industry. Novoprotein is making unrelenting efforts to effectively improve human life and health.
友情提醒
我可以最后一分钟注册讲座吗? 请尽量至少提前一天注册
我注册成功了吗？注册成功后会收到确认邮件，邮件含有当日连入webinar的链接，点击链接即可顺利进入webinar
我没有收到邮件？检查一下您的自动过滤邮箱
我用什么软件参加讲座？讲座使用Zoom平台，PC，苹果和安卓系统都可以下载
第一次参加，我的电脑和手机操作系统适合吗？邮件中提供了系统测试链接， 一试便知
可以观看本期和往期视频回放吗？华人抗体协会注册会员可以在讲座结束后登录华人抗体协会网主页观看本期和往期视频回放
还有其他问题和建议？请随时在微信文章末尾留言或在会员微信群求助
关于华人抗体协会的Industrial Frontier讲座系列
Webinar系列自2017年年中启动以来，主要围绕抗体药从研发到上市的整个产业链进行设置。本期的Industrial Frontier Webinar Series是我们推出的最新的Webinar讲座系列，目的是为华人抗体协会企业会员对该企业最新的技术平台提供一个分享的平台。
Webinar目前采用Zoom在线系统：https://www.zoom.com/ 每个webinar总时长为1小时-1个半小时，采用presentation + 15分钟 Q & A的形式进行，以增进观众与报告人的互动和交流。讲座的幻灯片以及讲座时使用的语言将根据报告人的偏好采用中文或者英文。
Industrial Frontier Webinar Series系列将对公众免费开放。请点击二维码注册讲座，或者请登录https://chineseantibody.net/cas-live-webinar-series-industry-frontier/或点击文末阅读原文（Read more)免费注册参加这个webinar。注册后会收到确认和提醒邮件, 可直接点击邮件中的webinar链接进入讲座。每次webinar过程中， 协会鼓励和欢迎注册听众进入webinar微信讨论群。听众可以通过讲座系统平台或者微信群平台向主讲人提出或讨论问题。请在线的会员充分利用实时webinar的机会与主讲人积极的问答互动。
赞助与合作机会
华人抗体协会欢迎抗体领域的企业成为华人抗体协会的企业会员，有意参与的公司请联系：sponsorship@chineseantibody.org。协会将为企业会员提供宣传展示自己公司的机会。
关于华人抗体协会
华人抗体协会是一个聚焦于治疗性抗体的非营利、非政府的独立的全球性专业组织，致力于创建一个旨在促进在治疗性抗体研发，生产以及商业化等领域的合作与交流的平台。
关于协会更多介绍请参阅：华人抗体协会简介与发展简史
华人抗体协会与牛津大学出版社合作，出版同行评审英文专业期刊: Antibody Therapeutics。
Antibody Therapeutics网站：https://academic.oup.com/abt
华人抗体协会网站：
https://www.chineseantibody.org
Follow us at LinkedIn: https://www.linkedin.com/mwlite/company/chineseantibodysociety
